HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Small Cell Lung Carcinoma (Small Cell Lung Cancer)

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
Also Known As:
Small Cell Lung Cancer; Carcinoma, Small Cell Lung; Oat Cell Lung Cancer; Small Cell Cancer Of The Lung; Oat Cell Carcinoma of Lung
Networked: 10365 relevant articles (755 outcomes, 2097 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
3. Neoplasm Metastasis (Metastasis)
4. Brain Neoplasms (Brain Tumor)
5. Lung Neoplasms (Lung Cancer)

Experts

1. Rudin, Charles M: 46 articles (01/2022 - 03/2004)
2. Guo, Linlang: 34 articles (04/2022 - 01/2009)
3. Salgia, Ravi: 33 articles (04/2022 - 02/2002)
4. Faivre-Finn, Corinne: 31 articles (01/2022 - 07/2005)
5. Kiura, Katsuyuki: 30 articles (01/2020 - 01/2002)
6. Zhang, Li: 28 articles (10/2022 - 10/2008)
7. Yu, Jinming: 27 articles (10/2022 - 09/2014)
8. Wang, Wei: 27 articles (08/2022 - 02/2006)
9. Tanimoto, Mitsune: 26 articles (10/2016 - 05/2002)
10. Blackhall, Fiona: 25 articles (11/2021 - 01/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Small Cell Lung Carcinoma:
1. Etoposide (VP 16)FDA LinkGeneric
2. Cisplatin (Platino)FDA LinkGeneric
3. Carboplatin (JM8)FDA LinkGeneric
4. PlatinumIBA
01/01/2021 - "Studies that enrolled relapsed small-cell lung cancer and compared platinum-doublets with non-platinum-based regimens for second-line treatment were identified using PubMed and EMBASE. "
01/01/2021 - "In this study, we investigated whether platinum-doublets are suitable as second-line treatment for relapsed small-cell lung cancer. "
01/01/2019 - "This study compared real-world treatment patterns of patients with extensive disease small-cell lung cancer (ED-SCLC) across regions and by platinum resistance/platinum sensitivity (PR/PS) and established if these patterns were in line with published guidelines. "
04/01/2014 - "背景与目的 以铂类为基础联合第三代药物的双药化疗方案是治疗晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)的标准一线治疗方案。本研究采用meta分析的方法评价多西他赛联合铂类(docetaxel plus platinum, DP)方案对比长春瑞滨联合铂类(vinorelbine plus platinum, VP)方案治疗晚期NSCLC的疗效和安全性。方法 计算机检索Pubmed、EMBASE、Cochrane Library、中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据(VIP)库及万方数据库关于DP方案与VP方案治疗晚期NSCLC的随机对照试验(randomized controlled trial, RCT)。根据Cochrane Handbook 5.1.0的质量评价标准,用Stata 12.0软件进行统计学分析。结果 研究共纳入7项RCTs,包括晚期NSCLC患者2,381例。DP方案的2年生存率(HR=0.887, 95%CI: 0.810-0.972, P=0.010)、有效率(RR=1.276, 95%CI: 1.107-1.450, P=0.001)和腹泻发生率(RR=3.134, 95%CI: 1.918-5.121, P<0.001)较VP方案高;DP方案减少了贫血的发生率(RR=0.386, 95%CI: 0.311-0.478, P<0.001);DP方案与VP方案在1年生存率、白细胞减少、中性粒细胞减少、血小板减少、厌食、恶心、呕吐方面的差异无统计学意义。结论 DP方案虽然增加了腹泻发生率,但却减少了贫血的发生率,同时提高了2年生存率和有效率。相比VP方案,DP方案可能更适合一线治疗晚期NSCLC。"
07/11/2023 - "Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance."
5. Immune Checkpoint InhibitorsIBA
6. Irinotecan (Camptosar)FDA LinkGeneric
7. Topotecan (Hycamtin)FDA LinkGeneric
8. atezolizumabIBA
9. Paclitaxel (Taxol)FDA LinkGeneric
10. amrubicinIBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Radiotherapy
3. Therapeutics
4. Cranial Irradiation
5. Combination Drug Therapy (Combination Chemotherapy)